In addition, sEVs treatment increased Glt-1 expression in astrocytes in the peritumoral area and increased Glast in in vitro cultures, thus contributing to increasing the uptake of Glu and reducing glioma-induced neurotoxicity. The gene discussed is SLC1A2; the disease is central nervous system cancer.